EPISODE · Dec 18, 2025 · 3 MIN
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
from AudioAbstracts
Host: Marlene Mimi Maeusli, PhD. This is a non-certified educational series produced and controlled by ReachMD. As CAR T-cell therapy becomes more widely used in multiple myeloma, understanding when toxicities occur is critical to balancing safety and access. Hear from Dr. Mimi Maeusli as she reviews new clinical and real-world findings on post-infusion monitoring for idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), which were presented at the International Myeloma Society Annual Meeting in September 2025.
What this episode covers
Host: Marlene Mimi Maeusli, PhD. This is a non-certified educational series produced and controlled by ReachMD. As CAR T-cell therapy becomes more widely used in multiple myeloma, understanding when toxicities occur is critical to balancing safety and access. Hear from Dr. Mimi Maeusli as she reviews new clinical and real-world findings on post-infusion monitoring for idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), which were presented at the International Myeloma Society Annual Meeting in September 2025.
NOW PLAYING
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.